[Federal Register: March 15, 2004 (Volume 69, Number 50)]
[Notices]               
[Page 12180-12181]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr15mr04-111]                         

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

 
Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on January 6, 2004, Roche 
Diagnostics Corporation, Attn.: Regulatory Compliance, 9115 Hague Road, 
Indianapolis, Indiana 46250, made renewal by letter to the Drug 
Enforcement Administration (DEA) for registration as a bulk 
manufacturer of the basic class of controlled substances listed below:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Lysergic Acid Diethylamide (7315)..........  I
Tetrahydrocannabinol (7370)................  I
Alphamethadol (9605).......................  I
Phencyclidine (7471).......................  II
Benzoylecogonine (9180)....................  II
Methadone (9250)...........................  II
Morphine (9300)............................  II
------------------------------------------------------------------------


[[Page 12181]]

    The firm plans to produce small quantities of controlled substances 
for use in diagnostic products.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: Federal Register Representative, 
Office of Chief Counsel (CCD) and must be filed no later than May 14, 
2004.

    Dated: March 5, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 04-5777 Filed 3-12-04; 8:45 am]

BILLING CODE 4410-09-M